🔎 Trials Near Me

Home › Waldenstrom Macroglobulinemia

Waldenstrom Macroglobulinemia clinical trials recruiting in the U.S.

30 studies for Waldenstrom Macroglobulinemia are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04728893

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06561347

A Study of ARC-02 in B-cell NHL

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07691606

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

RecruitingPhase 4
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07426484

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05640102

A Long-term Extension Study of PCI-32765 (Ibrutinib)

RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT01804686

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06708897

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07424833

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Recruiting
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06860880

Registry of Older Patients With Cancer

RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

RecruitingObservational study
Ages 18 and older · All sexes · Updated May 7, 2026 · NCT02269592

SynKIR-310 for Relapsed/Refractory B-NHL

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT06544265

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137

Epcoritamab in Previously Treated WM

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT06510491

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT04775745

Study of SGR-1505 in Mature B-Cell Neoplasms

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT05602363

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.